Sachetta LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 2.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,810 shares of the company’s stock after selling 53 shares during the quarter. Sachetta LLC’s holdings in Zoetis were worth $330,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Focus Financial Network Inc. ADV purchased a new position in shares of Zoetis in the 4th quarter worth $2,159,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Axiom Investors LLC DE grew its holdings in shares of Zoetis by 36.3% during the 4th quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock worth $117,331,000 after purchasing an additional 158,459 shares during the period. Global Assets Advisory LLC acquired a new stake in Zoetis during the 1st quarter worth approximately $8,831,000. Finally, Franklin Street Advisors Inc. NC raised its holdings in Zoetis by 4.3% in the first quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock valued at $20,478,000 after buying an additional 5,035 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Trading Up 1.3 %
Shares of ZTS opened at $191.73 on Tuesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a 50-day moving average price of $181.60 and a 200 day moving average price of $174.36. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market capitalization of $86.86 billion, a P/E ratio of 36.94, a P/E/G ratio of 2.90 and a beta of 0.88.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on ZTS shares. Stifel Nicolaus reissued a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research report on Tuesday, August 27th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler boosted their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $217.11.
Get Our Latest Report on Zoetis
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
- Five stocks we like better than Zoetis
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Top 3 Stocks to Secure Strong Returns Through Market Uncertainty
- The Role Economic Reports Play in a Successful Investment Strategy
- How the Fed’s Rate Cuts Could Boost Bonds, Silver, and Small Caps
- Conference Calls and Individual Investors
- Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.